Sökning: WFRF:(Hellstrom Mats) >
The role of serum t...
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer : biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
-
- Zhu, Yajing (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.
-
- Zerdes, Ioannis (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.;Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden.
-
- Matikas, Alexios (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.;Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden.
-
visa fler...
-
- Cruz, Ivette Raices (författare)
- Karolinska Inst, Inst Environm Med, Div Biostat, Stockholm, Sweden.,Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
-
- Bergqvist, Mattias (författare)
- Biov Int, Uppsala Sci Pk, Uppsala, Sweden.,Biovica International, Uppsala Science Park, Uppsala, Sweden
-
- Elinder, Ellinor (författare)
- Soder Sjukhuset, Dept Oncol, Stockholm, Sweden.,Department of Oncology, South Hospital, Stockholm, Sweden
-
- Bosch, Ana (författare)
- Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Lund, Sweden.,Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
-
- Lindman, Henrik (författare)
- Uppsala Univ Hosp, Dept Oncol, Uppsala, Sweden.,Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
-
- Einbeigi, Zakaria (författare)
- Southern Alvsborg Hosp, Dept Oncol, Borås, Sweden.,Department of Oncology, Southern Älvsborg Hospital, Borås, Sweden
-
- Andersson, Anne, 1966- (författare)
- Umeå universitet,Onkologi,Umeå Univ, Umeå, Sweden.
-
- Carlsson, Lena (författare)
- Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden.,Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden
-
- Dreifaldt, Ann Charlotte (författare)
- Örebro Univ Hosp, Dept Oncol, Örebro, Sweden.,Department of Oncology, Örebro University Hospital, Örebro, Sweden
-
- Isaksson-Friman, Erika (författare)
- St Goran Hosp, Dept Oncol, Stockholm, Sweden.,Department of Oncology, St Göran Hospital, Stockholm, Sweden
-
- Hellstrom, Mats (författare)
- Karolinska Univ Hosp, Ctr Clin Canc Studies, Theme Canc, Stockholm, Sweden.,Centre for Clinical Cancer Studies, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
-
- Johansson, Hemming (författare)
- Karolinska Institutet,Karolinska Univ Hosp, Ctr Clin Canc Studies, Theme Canc, Stockholm, Sweden.
-
- Wang, Kang (författare)
- Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.,Department of Oncology-Pathology, Karolinska Institutet, Karolinska Vägen A2:07, Solna, Stockholm, Sweden
-
- Bergh, Jonas C. S. (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.;Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden.
-
- Hatschek, Thomas (författare)
- Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.;Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden.,Department of Oncology-Pathology, Karolinska Institutet, Karolinska Vägen A2:07, Solna, Stockholm, Sweden; Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
-
- Foukakis, Theodoros (författare)
- Karolinska Institutet,Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden.;Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden.
-
visa färre...
-
Karolinska Institutet Karolinska Inst, Dept Oncol Pathol, Karolinska Vagen A2-07, S-17164 Stockholm, Sweden (creator_code:org_t)
- Springer, 2024
- 2024
- Engelska.
-
Ingår i: Breast Cancer Research and Treatment. - : Springer. - 0167-6806 .- 1573-7217. ; 204:2, s. 299-308
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundThymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an early indicator of treatment response in human epidermal growth factor 2 (HER2)-negative early and metastatic breast cancer (BC). However, the prognostic and predictive value of serial TK1 activity in HER2-positive BC remains unknown.MethodsIn the PREDIX HER2 trial, 197 HER2-positive BC patients were randomized to neoadjuvant trastuzumab, pertuzumab, and docetaxel (DPH) or trastuzumab emtansine (T-DM1), followed by surgery and adjuvant epirubicin and cyclophosphamide. Serum samples were prospectively collected from all participants at multiple timepoints: at baseline, after cycle 1, 2, 4, and 6, at end of adjuvant therapy, annually for a total period of 5 years and/or at the time of recurrence. The associations of sTK1 activity with baseline characteristics, pathologic complete response (pCR), event-free survival (EFS), and disease-free survival (DFS) were evaluated.ResultsNo association was detected between baseline sTK1 levels and all the baseline clinicopathologic characteristics. An increase of TK1 activity from baseline to cycle 2 was seen in all cases. sTK1 level at baseline, after 2 and 4 cycles was not associated with pCR status. After a median follow-up of 58 months, 23 patients had EFS events. There was no significant effect between baseline or cycle 2 sTK1 activity and time to event. A non-significant trend was noted among patents with residual disease (non-pCR) and high sTK1 activity at the end of treatment visit, indicating a potentially worse long-term prognosis.ConclusionsTK1 activity increased following neoadjuvant therapy for HER2-positive BC but was not associated with patient outcomes or treatment benefit. However, the post-surgery prognostic value in patients that have not attained pCR warrants further investigation.Trial registrationClinicalTrials.gov, NCT02568839. Registered on 6 October 2015.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- LANTBRUKSVETENSKAPER -- Veterinärmedicin -- Medicinsk biovetenskap (hsv//swe)
- AGRICULTURAL SCIENCES -- Veterinary Science -- Medical Bioscience (hsv//eng)
Nyckelord
- Thymidine kinase
- HER2+breast cancer
- Biomarker
- Neoadjuvant treatment
- Prognosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Zhu, Yajing
-
Zerdes, Ioannis
-
Matikas, Alexios
-
Cruz, Ivette Rai ...
-
Bergqvist, Matti ...
-
Elinder, Ellinor
-
visa fler...
-
Bosch, Ana
-
Lindman, Henrik
-
Einbeigi, Zakari ...
-
Andersson, Anne, ...
-
Carlsson, Lena
-
Dreifaldt, Ann C ...
-
Isaksson-Friman, ...
-
Hellstrom, Mats
-
Johansson, Hemmi ...
-
Wang, Kang
-
Bergh, Jonas C. ...
-
Hatschek, Thomas
-
Foukakis, Theodo ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- LANTBRUKSVETENSKAPER
-
LANTBRUKSVETENSK ...
-
och Veterinärmedicin
-
och Medicinsk biovet ...
- Artiklar i publikationen
-
Breast Cancer Re ...
- Av lärosätet
-
Uppsala universitet
-
Umeå universitet
-
Karolinska Institutet